Concept of chemoprevention in colorectal cancer

Table 1 Use of aspirin in average risk subjects and colonic neoplasia risk reduction

Study	n	Aspirin dose (mg/AD)	Study duration (yr)	Relative risk reduction (95% CI)
Thun et al[13]	622 424	100 mg3	≥ 1	0.58 (0.36-0.93)1
				0.61 (0.38-0.97)2
Gann et al[14]	22071	325	5	1.15 (0.80-1.65)1
Cook et al[15]	39876	100	10	0.97 (0.77-1.24)2
Stürmer et al[16]	22071	325	12	1.03 (0.83-1.28)
Giovannucci et al[17]	47900	325	4	0.54 (0.34-0.84)1
Paganini-Hill et al[18]	13979	325	7-10	1.38 (NR)1
Chan et al[19]	89446	100	10	0.62 (0.44-0.86)2
Friis et al[20]	29470	325	6	0.9 (0.70-1.10)1
García-Rodríguez et al[21]	12005	325	> 2	0.9 (0.8-1.1)
Reeves et al[22]	845	100	> 5	0.79 (0.46-1.36)2
Juarranz et al[23]	502	325	NR	0.32 (0.09-1.10)
La Vecchia et al[24]	3248	325	5	0.7 (0.50-1.00)
Kune et al[25]	1442	325	NR	0.57 (0.41-0.79)
Suh et al[26]	2704	325	6	0.33 (0.15-0.72)
Slattery et al[27]	3051	325	> 5	0.7 (0.6-0.8)

¹Males;

²Females;

³Daily; AD: Alternate day dosage; CI: Confidence interval; NR: Not reported.